Evidence map›Paper›PMID 28054001›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2017

Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study.

Paola Valentino, Fabiana Marnetto, Letizia Granieri, Marco Capobianco, Antonio Bertolotto

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Experience with rituximab therapy in a real-life sample of multiple sclerosis patients.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020
    Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Paola ValentinoNeuroscience Institute Cavalieri Ottolenghi (NICO) (P.V., F.M., L.G., A.B.) and Neurologia 2-CRESM (P.V., F.M., L.G., M.C., A.B.), AOU San Luigi Gonzaga, Orbassano, Turin, Italy.
Fabiana MarnettoNeuroscience Institute Cavalieri Ottolenghi (NICO) (P.V., F.M., L.G., A.B.) and Neurologia 2-CRESM (P.V., F.M., L.G., M.C., A.B.), AOU San Luigi Gonzaga, Orbassano, Turin, Italy.
Letizia GranieriNeuroscience Institute Cavalieri Ottolenghi (NICO) (P.V., F.M., L.G., A.B.) and Neurologia 2-CRESM (P.V., F.M., L.G., M.C., A.B.), AOU San Luigi Gonzaga, Orbassano, Turin, Italy.
Marco CapobiancoNeuroscience Institute Cavalieri Ottolenghi (NICO) (P.V., F.M., L.G., A.B.) and Neurologia 2-CRESM (P.V., F.M., L.G., M.C., A.B.), AOU San Luigi Gonzaga, Orbassano, Turin, Italy.
Antonio BertolottoNeuroscience Institute Cavalieri Ottolenghi (NICO) (P.V., F.M., L.G., A.B.) and Neurologia 2-CRESM (P.V., F.M., L.G., M.C., A.B.), AOU San Luigi Gonzaga, Orbassano, Turin, Italy.
Neuroscience Institute · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe undertook an observational retrospective study to investigate the usefulness of aquaporin-4 (AQP4) antibodies (Ab) titration in the management of patients with neuromyelitis optica (NMO) treated with rituximab (RTX) by studying (1) the correlation between AQP4-Ab titer and disease activity, (2) the influence of RTX on antibody levels, and (3) the association between AQP4-Ab levels and responsiveness to RTX.

methodsA cell-based assay was used for AQP4-Ab titration in 322 serum samples from 7 patients with NMO treated with RTX (median follow-up 65 months), according to a treatment-to-target approach. Serum samples were collected every month following standardized procedures.

results(1) In group analysis, AQP4-Ab titers correlated with the disease activity, showing higher titers during and preceding relapses than during remission. However, in individual analysis, an increase in AQP4-Ab titers and CD19+ B cells did not always precede a relapse. (2) A reduction of AQP4-Ab titers in the short-term and long-term period was observed during RTX treatment. (3) Reduction of AQP4-Ab titers was observed in responder patients both 3 months after RTX infusion and in the long-term follow-up. In one nonresponder patient, AQP4-Ab levels never decreased during the treatment period.

conclusionsTitration of AQP4-Abs could be useful in the clinical management of patients with NMO treated with RTX: titration before each reinfusion and 3 months after each reinfusion may provide information about responsiveness to RTX. Although a relationship among AQP4-Ab levels, disease activity, and response to RTX was observed, the usefulness of AQP4-Ab titration to predict relapses is limited.

Identifiers

PMID28054001
PMCPMC5182057
OpenAlexW2561708624

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.